BMYBristol-Myers Squibb Company

$124B

Q3 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.0B-2.2% YoY

Gross Profit

$6.2B56.7% margin

Operating Income

$2.1B19.2% margin

Net Income

$1.9B17.6% margin

EPS (Diluted)

$0.93

QoQ Revenue Growth

-2.3%

Cash Flow

Operating Cash Flow

$4.8B

Free Cash Flow

$4.4B

Stock-Based Comp.

$132M

Balance Sheet

Total Assets

$91.3B

Total Liabilities

$62.2B

Stockholders' Equity

$29.0B

Cash & Equivalents

$7.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.0B	$11.2B	-2.2%
Gross Profit	$6.2B	$6.4B	-3.5%
Operating Income	$2.1B	$2.2B	-5.7%
Net Income	$1.9B	$1.6B	+20.0%

Revenue Segments

Eliquis

$2.7B25%

Opdivo

$2.3B21%

Revlimid

$1.4B13%

Orencia

$925M8%

Pomalyst/Imnovid

$872M8%

Yervoy

$579M5%

Sprycel

$517M5%

Mature Products And All Other

$476M4%

Abraxane

$260M2%

Reblozyl

$248M2%

Opdualag

$166M2%

Zeposia

$123M1%

Abecma

$93M1%

Breyanzi

$92M1%

Camzyos

$68M1%

Sotyktu

$66M1%

Geographic Segments

UNITED STATES

$7.6B70%

Rest Of World

$3.2B29%

Other Region

$185M2%

BMY Q3 2023 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena